PMID- 22454686
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20211021
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2012
DP  - 2012
TI  - Topical Application of Chrysanthemum indicum L. Attenuates the Development of 
      Atopic Dermatitis-Like Skin Lesions by Suppressing Serum IgE Levels, IFN-gamma, and 
      IL-4 in Nc/Nga Mice.
PG  - 821967
LID - 10.1155/2012/821967 [doi]
LID - 821967
AB  - Chrysanthemum indicum L. (CIL) is widely used as an anti-inflammatory agent in 
      Asia and our preliminary study revealed that CIL reduced interleukin (IL)-4 and 
      IL-13 in 2,4-dinitrochlorobenzene (DNCB)-treated HaCaT cells, a human 
      keratinocyte cell line. We investigated the atopic dermatitis (AD) effect of 
      topically applied CIL in mice with AD-like symptoms. After topical application of 
      1,3-butylen glycol (control), CIL-Low (5%), CIL-High (30%), or 0.1% 
      hydrocortisone (HC) on the AD-like skin lesions in DNCB-treated NC/Nga mice for 5 
      weeks, the ear thickness, mast cell infiltration, and serum immunoglobulin E 
      (IgE), IgG1, IL-4 and interferon (IFN)-gamma were measured. The gene expressions of 
      IL-4, IL-13, and IFN-gamma in the dorsal skin were assayed. CIL treatment 
      dosedependently reduced severity of clinical symptoms of dorsal skin, ear 
      thickness, and the number of mast cells and eosinophils. CIL-High significantly 
      decreased serum IgE, IgG1, IL-4, and IFN-gamma levels and reduced mRNA levels of 
      IFN-gamma, IL-4, and IL-13 in dorsal skin lesion. The improvement by CIL-High was 
      similar to HC, but without its adverse effects such as skin atrophy maceration, 
      and secondary infection. In conclusion, CIL may be an effective alternative 
      substance for the management of AD.
FAU - Park, Sunmin
AU  - Park S
AD  - Department of Food and Nutrition, Hoseo University, 165 Sechul-Ri, BaeBang-Yup, 
      Asan-Si, ChungNam-Do 336-795, Republic of Korea.
FAU - Lee, Jung Bok
AU  - Lee JB
FAU - Kang, Suna
AU  - Kang S
LA  - eng
PT  - Journal Article
DEP - 20120209
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3291039
EDAT- 2012/03/29 06:00
MHDA- 2012/03/29 06:01
PMCR- 2012/02/09
CRDT- 2012/03/29 06:00
PHST- 2011/09/22 00:00 [received]
PHST- 2011/10/25 00:00 [revised]
PHST- 2011/11/01 00:00 [accepted]
PHST- 2012/03/29 06:00 [entrez]
PHST- 2012/03/29 06:00 [pubmed]
PHST- 2012/03/29 06:01 [medline]
PHST- 2012/02/09 00:00 [pmc-release]
AID - 10.1155/2012/821967 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2012;2012:821967. doi: 10.1155/2012/821967. 
      Epub 2012 Feb 9.